Drugs & Therapy Perspectives

, Volume 19, Issue 1, pp 24–26 | Cite as

Drug-target pharmacogenomics is at a preliminary stage, but its future is exciting

Practical Issues and Updates


Trastuzumab Clozapine Clozapine Response Nontoxic Genotype Conventional Medical Practice 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Johnson JA. Drug target pharmacogenomics: an overview. Am J Pharmacogenomics 2001; 1 (4): 271–81PubMedCrossRefGoogle Scholar
  2. 2.
    Ozdemir V, Shear NH, Kalow W. What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Safety 2001; 24 (2): 75–85PubMedCrossRefGoogle Scholar
  3. 3.
    Ensom MHH, Chang TKH, Patel P. Pharmacogenetics: the therapeutic drug monitoring of the future? Clin Pharmacokinet 2001; 40 (11): 783–802PubMedCrossRefGoogle Scholar
  4. 4.
    Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response [letter]. Lancet 2000; 355 (9215): 1615–6PubMedCrossRefGoogle Scholar
  5. 5.
    Lithell H, Berglund L, Jonsson J, et al. Prediction of blood pressure response to ACE inhibitors using patterns of genetic variation in the RAAS [abstract]. Circulation 1999 (18); 100: I–755Google Scholar
  6. 6.
    Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857–65PubMedCrossRefGoogle Scholar
  7. 7.
    McCarthy JJ, Hilfiker R. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 2000; 18 (5): 505–8PubMedCrossRefGoogle Scholar
  8. 8.
    Weber WW. Pharmacogenetic tactics and strategies. Implications for paediatrics. Paediatr Drugs 2001; 3 (12): 863–81PubMedCrossRefGoogle Scholar
  9. 9.
    Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999; 26 (4 Suppl. 12): 71–7PubMedGoogle Scholar
  10. 10.
    Schwartz RS. Racial profiling in medical research. N Engl J Med 2001; 344 (18): 1392–3PubMedCrossRefGoogle Scholar
  11. 11.
    Turner ST, Schwartz GL, Chapman AB, et al. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37 (2 Part 2): 739–43PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Personalised recommendations